Lineage Cell Therapeutics, Inc.
LCTXAMEXHealthcare● Active
$1.19
$-0.02(-1.65%)
Market Cap$296664971
P/E Ratio—
52W High$2.09
52W Low$0.65
Lineage Cell Therapeutics, Inc. (LCTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LCTX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.03
Est. -$0.02 · -50.0%
Revenue
$0.00B
Est. $0.00B · -52.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
LCTX reports quarterly as a AMEX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.03 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 12, 2026 | -$0.02 | -$0.03 | -50.0% | $0.00B | $0.00B | -52.1% |
| ▲ Q1 FY2026 | Mar 5, 2026 | -$0.04 | $0.00 | +109.2% | $0.01B | $0.00B | +236.8% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.02 | -$0.13 | -550.0% | $0.00B | $0.00B | +87.8% |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.02 | -$0.01 | +50.0% | $0.00B | $0.00B | +46.4% |
| — Q2 FY2025 | May 13, 2025 | -$0.02 | -$0.02 | +0.0% | $0.00B | $0.00B | -12.9% |
| ▲ Q1 FY2025 | Mar 10, 2025 | -$0.04 | -$0.01 | +75.0% | $0.00B | $0.00B | +110.7% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.01 | -$0.02 | -53.5% | $0.00B | $0.00B | +133.1% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.03
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Miss
EPS Actual
-$0.03
EPS Est.
-$0.02
EPS Surpr.
-50.0%
Revenue
$0.00B
Q1 FY2026
Mar 5, 2026Beat
EPS Actual
$0.00
EPS Est.
-$0.04
EPS Surpr.
+109.2%
Revenue
$0.01B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.13
EPS Est.
-$0.02
EPS Surpr.
-550.0%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.01
EPS Est.
-$0.02
EPS Surpr.
+50.0%
Revenue
$0.00B
Q2 FY2025
May 13, 2025
EPS Actual
-$0.02
EPS Est.
-$0.02
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2025
Mar 10, 2025Beat
EPS Actual
-$0.01
EPS Est.
-$0.04
EPS Surpr.
+75.0%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.02
EPS Est.
-$0.01
EPS Surpr.
-53.5%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.05 | $-0.03 | $-0.01 | 1 |
| Q3 FY2028 | $-0.05 | $-0.03 | $-0.01 | 1 |
| Q2 FY2028 | $-0.05 | $-0.03 | $-0.01 | 1 |
| Q1 FY2028 | $-0.05 | $-0.03 | $-0.01 | 1 |
| Q4 FY2027 | $-0.05 | $-0.03 | $-0.01 | 1 |
| Q3 FY2027 | $-0.04 | $-0.03 | $-0.01 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 12, 2026 | -50.0% | $1.31 | $1.33 | +1.53% |
| ▲ Q1 FY2026 | Mar 5, 2026 | +109.2% | $1.95 | $1.84 | -5.64% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -550.0% | $1.82 | $1.73 | -4.95% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +50.0% | $1.01 | $1.01 | +0.00% |
| ▲ Q2 FY2025 | May 13, 2025 | +0.0% | $0.48 | $0.47 | -1.90% |
| ▲ Q1 FY2025 | Mar 10, 2025 | +75.0% | $0.53 | $0.53 | +1.09% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -53.5% | $0.91 | $0.89 | -3.07% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +40.0% | $0.87 | $0.88 | +1.80% |
Q2 FY2026+1.53%
Report Date
May 12, 2026
EPS Beat/Miss
-50.0%
Price Before
$1.31
Price After
$1.33
Q1 FY2026-5.64%
Report Date
Mar 5, 2026
EPS Beat/Miss
+109.2%
Price Before
$1.95
Price After
$1.84
Q4 FY2025-4.95%
Report Date
Nov 6, 2025
EPS Beat/Miss
-550.0%
Price Before
$1.82
Price After
$1.73
Q3 FY2025+0.00%
Report Date
Aug 12, 2025
EPS Beat/Miss
+50.0%
Price Before
$1.01
Price After
$1.01
Q2 FY2025-1.90%
Report Date
May 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$0.48
Price After
$0.47
Q1 FY2025+1.09%
Report Date
Mar 10, 2025
EPS Beat/Miss
+75.0%
Price Before
$0.53
Price After
$0.53
Q4 FY2024-3.07%
Report Date
Nov 14, 2024
EPS Beat/Miss
-53.5%
Price Before
$0.91
Price After
$0.89
Q3 FY2024+1.80%
Report Date
Aug 8, 2024
EPS Beat/Miss
+40.0%
Price Before
$0.87
Price After
$0.88
Avg Beat Reaction-0.93%
Avg Miss Reaction-2.16%
Beat Rate5 / 8 quarters
Largest Move-5.64% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LCTX ends December
Lineage Cell Therapeutics, Inc. (LCTX) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.03 — missing the analyst consensus of $-0.02 by -50.0%. The next LCTX earnings date is expected around September 1, 2026.
Each quarter, investors track LCTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LCTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LCTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LCTX earnings · 5 questionsLineage Cell Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. LCTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LCTX historically reports after market close (AMC).
LCTX earnings datewhen is LCTX earningsLCTX next earnings datewhen does LCTX report earningsLCTX earnings calendar
▸ Source: FMP · Lineage Cell Therapeutics, Inc. SEC filings · US GAAP · Lineage Cell Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026